FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766293656> ?p ?o ?g. }

• W2766293656 endingPage "696" @default.
• W2766293656 startingPage "689" @default.
• W2766293656 abstract "Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab plus fludarabine and mitoxantrone) regimens without rituximab maintenance as initial therapy for patients with advanced-stage follicular lymphoma (FL). A previous analysis with a median follow-up of 34 months showed a superior 3-year time to treatment failure, the primary study end point, with R-CHOP and R-FM versus R-CVP and showed R-CHOP to have a better risk-benefit ratio in terms of toxicity than R-FM. We report a post hoc analysis of this trial after a median follow-up of 7 years. Patients and Methods Of the 534 enrolled patients, 504 were evaluable. At the time of analysis, the median follow-up was 84 months (range, 1 to 119 months). Results The 8-year time to treatment failure and progression-free survival rates were 44% (95% CI, 39% to 49%) and 48% (95% CI, 43% to 53%), respectively. The hazard ratio for progression-free survival adjusted by FL International Prognostic Index 2 versus R-CVP was 0.73 for R-CHOP (95% CI, 0.54 to 0.98; P = .037) and 0.67 for R-FM (95% CI, 0.50 to 0.91; P = .009). The 8-year overall survival (OS) rate was 83% (95% CI, 79% to 87%), with no significant differences among study arms. Overall, we observed a higher risk of dying as a result of causes unrelated to lymphoma progression with R-FM versus R-CVP. Conclusion With an 83% 8-year OS rate, long-term follow-up of the FOLL05 trial confirms the favorable outcome of patients with advanced-stage FL treated with immunochemotherapy. The three study arms had similar OS but different activity and toxicity profiles. Patients initially treated with R-CVP had a higher risk of lymphoma progression compared with those receiving R-CHOP, as well as a higher risk of requiring additional therapy." @default.
• W2766293656 created "2017-11-10" @default.
• W2766293656 creator A5005899608 @default.
• W2766293656 creator A5007749764 @default.
• W2766293656 creator A5011759794 @default.
• W2766293656 creator A5013445468 @default.
• W2766293656 creator A5016803459 @default.
• W2766293656 creator A5018106127 @default.
• W2766293656 creator A5019034145 @default.
• W2766293656 creator A5028412728 @default.
• W2766293656 creator A5031900268 @default.
• W2766293656 creator A5035398527 @default.
• W2766293656 creator A5038163660 @default.
• W2766293656 creator A5041745367 @default.
• W2766293656 creator A5045518627 @default.
• W2766293656 creator A5047971271 @default.
• W2766293656 creator A5049017377 @default.
• W2766293656 creator A5058392949 @default.
• W2766293656 creator A5066201212 @default.
• W2766293656 creator A5069596141 @default.
• W2766293656 creator A5070490189 @default.
• W2766293656 creator A5076114231 @default.
• W2766293656 creator A5076236981 @default.
• W2766293656 creator A5081247845 @default.
• W2766293656 creator A5085410438 @default.
• W2766293656 creator A5091664535 @default.
• W2766293656 date "2018-03-01" @default.
• W2766293656 modified "2023-09-30" @default.
• W2766293656 title "Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma" @default.
• W2766293656 cites W1554787345 @default.
• W2766293656 cites W1964744337 @default.
• W2766293656 cites W1973617793 @default.
• W2766293656 cites W1973979329 @default.
• W2766293656 cites W1974574396 @default.
• W2766293656 cites W1987173571 @default.
• W2766293656 cites W1995548446 @default.
• W2766293656 cites W2003909385 @default.
• W2766293656 cites W2069162303 @default.
• W2766293656 cites W2073140442 @default.
• W2766293656 cites W2085346499 @default.
• W2766293656 cites W2101141816 @default.
• W2766293656 cites W2116402582 @default.
• W2766293656 cites W2117488094 @default.
• W2766293656 cites W2118495504 @default.
• W2766293656 cites W2118826067 @default.
• W2766293656 cites W2123236288 @default.
• W2766293656 cites W2138498369 @default.
• W2766293656 cites W2160468266 @default.
• W2766293656 cites W2167663043 @default.
• W2766293656 cites W2169209759 @default.
• W2766293656 cites W2176913865 @default.
• W2766293656 cites W2425760010 @default.
• W2766293656 cites W2576831228 @default.
• W2766293656 cites W2599689170 @default.
• W2766293656 cites W2605767476 @default.
• W2766293656 cites W2620269048 @default.
• W2766293656 cites W4365787119 @default.
• W2766293656 doi "https://doi.org/10.1200/jco.2017.74.1652" @default.
• W2766293656 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29095677" @default.
• W2766293656 hasPublicationYear "2018" @default.
• W2766293656 type Work @default.
• W2766293656 sameAs 2766293656 @default.
• W2766293656 citedByCount "103" @default.
• W2766293656 countsByYear W27662936562017 @default.
• W2766293656 countsByYear W27662936562018 @default.
• W2766293656 countsByYear W27662936562019 @default.
• W2766293656 countsByYear W27662936562020 @default.
• W2766293656 countsByYear W27662936562021 @default.
• W2766293656 countsByYear W27662936562022 @default.
• W2766293656 countsByYear W27662936562023 @default.
• W2766293656 crossrefType "journal-article" @default.
• W2766293656 hasAuthorship W2766293656A5005899608 @default.
• W2766293656 hasAuthorship W2766293656A5007749764 @default.
• W2766293656 hasAuthorship W2766293656A5011759794 @default.
• W2766293656 hasAuthorship W2766293656A5013445468 @default.
• W2766293656 hasAuthorship W2766293656A5016803459 @default.
• W2766293656 hasAuthorship W2766293656A5018106127 @default.
• W2766293656 hasAuthorship W2766293656A5019034145 @default.
• W2766293656 hasAuthorship W2766293656A5028412728 @default.
• W2766293656 hasAuthorship W2766293656A5031900268 @default.
• W2766293656 hasAuthorship W2766293656A5035398527 @default.
• W2766293656 hasAuthorship W2766293656A5038163660 @default.
• W2766293656 hasAuthorship W2766293656A5041745367 @default.
• W2766293656 hasAuthorship W2766293656A5045518627 @default.
• W2766293656 hasAuthorship W2766293656A5047971271 @default.
• W2766293656 hasAuthorship W2766293656A5049017377 @default.
• W2766293656 hasAuthorship W2766293656A5058392949 @default.
• W2766293656 hasAuthorship W2766293656A5066201212 @default.
• W2766293656 hasAuthorship W2766293656A5069596141 @default.
• W2766293656 hasAuthorship W2766293656A5070490189 @default.
• W2766293656 hasAuthorship W2766293656A5076114231 @default.
• W2766293656 hasAuthorship W2766293656A5076236981 @default.
• W2766293656 hasAuthorship W2766293656A5081247845 @default.
• W2766293656 hasAuthorship W2766293656A5085410438 @default.
• W2766293656 hasAuthorship W2766293656A5091664535 @default.
• W2766293656 hasBestOaLocation W27662936562 @default.
• W2766293656 hasConcept C126322002 @default.
• W2766293656 hasConcept C141071460 @default.

• next